Идёт набор NCT05501587

Measures of Respiratory Health Registry

— Наблюдательное Respiratory Disease Cystic Fibrosis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально: Состояния в реестре: Respiratory Disease, Cystic Fibrosis. Базовые параметры: 0 лет — 99 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Канада
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

There are many techniques that can allow for the quantification of lung function in children; some are being used clinically and others are under development. Many of these tools are available at BC Children's Hospital. This registry study will act as a central repository for the results of traditional and novel pulmonary function tests done at BC Children's Hospital to allow for future analysis.

Подробное описание

The scope of the registry is to collect data on small airways function in healthy children, children with cystic fibrosis (CF) and children with non-CF respiratory disease using the multiple breath washout (MBW) system. These data will be stored along with demographic data, clinical data, and traditional pulmonary function testing (PFT) data. The MBW data will be collected with concurrent with clinically indicated PFT testing.

The purpose of the registry is to 1/ establish a locally collected normal range of small airways function across the paediatric age range and 2/ to collect these measurements in CF and non-CF respiratory disease.

Ultimately, the objective of this registry is to validate MBW technology as a tool that can be utilized in clinical care.

Первичные конечные точки

To validate new lung function testing technologies [Срок оценки: 10 years]

Критерии участия

Participants with CF

Критерии включения

-Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria: i. A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis (QPIT).

ii. A documented genotype with two disease-causing mutations in the CFTR gene.

\- In the opinion of the investigator, the participant will likely have the ability to perform the lung function test of interest on the day of testing

Критерии исключения

Physical findings at the screening that would compromise the safety of the participant or the quality of the data (e.g. respiratory distress or work of breathing)
Requirement of supplementary oxygen to maintain oxygen saturation above 95%

Participants with other Respiratory Disease

Критерии включения

Physician-diagnosed lung disease
Informed consent by participant, parent, or legal guardian
In the opinion of the investigator, the participant will likely have the ability to perform the lung function test of interest on the day of testing

Критерии исключения

Physical findings at screening that would compromise the safety of the participant or the quality of the research data
Requirement of supplementary oxygen to maintain oxygen saturation above 95%

Healthy Participants

Inclusion criteria
Informed consent by participant, parent, or legal guardian
In the opinion of the investigator, the participant will likely have the ability to perform the lung function test of interest on the day of testing